Generic Lipitor tips Ranbaxy over $2bn revenue mark, but DoJ rap causes loss
This article was originally published in Scrip
Ranbaxy Laboratories has emerged as the first drug firm of Indian origin to scale the $2 billion sales mark, despite its long-running issues with the US FDA, backed by what appears to be an encouraging start with its generic version of Lipitor (atorvastatin) in the US market.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.